- Home
- BRO vs RPRX Comparison
BRO vs RPRX Comparison
Compare BRO & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRO | RPRX |
|---|---|---|
| Founded | 1939 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 25.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BRO | RPRX |
|---|---|---|
| Price | $69.88 | $59.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $82.07 | $51.40 |
| AVG Volume (30 Days) | 2.5M | ★ 2.7M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | 1.07% | ★ 1.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.90 | 0.71 |
| Revenue | ★ $5,902,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $25.61 | $38.63 |
| Revenue Next Year | $6.85 | $4.73 |
| P/E Ratio | ★ $36.51 | $84.07 |
| Revenue Growth | ★ 22.83 | 5.06 |
| 52 Week Low | $53.81 | $34.63 |
| 52 Week High | $97.39 | $60.44 |
Technical Indicators
Market Signals| Indicator | BRO | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 60.86 |
| Support Level | $64.60 | $55.66 |
| Resistance Level | $74.90 | $60.44 |
| Average True Range (ATR) | 1.87 | 1.39 |
| MACD | -0.43 | 0.07 |
| Stochastic Oscillator | 29.84 | 86.21 |
Price Performance
Historical ComparisonAbout BRO Brown & Brown Inc.
Brown & Brown Inc is a diversified insurance agency, wholesale brokerage, insurance programs, and service. The company's business is divided into two reportable segments: (i) the Retail segment, and (ii) the Specialty Distribution segment. The Retail segment provides a broad range of insurance products and services to commercial, public and quasi-public entities, and to professional and individual customers, as well as non-insurance warranty services and products through automobile and recreational vehicle dealer services businesses. The Specialty Distribution segment consists of wholesale brokerage and specialty businesses. Its geographic area is U.S, U.K and Others.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.